Clinical Trial Update: Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

Phase II trial evaluating skin toxicity–guided dosing of gefitinib (IRESSA) in squamous cell carcinoma of the head and neck. The study is completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: University of Chicago | Conditions: Head and Neck Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-11-21